Retinitis pigmentosa (RP) is a genetic disease causing progressive apoptotic death of photoreceptors and, ultimately, incurable blindness. Using the retinal degeneration 10 (rd10) mouse model of RP, we investigated the role of ceramide, a proapoptotic sphingolipid, in retinal degeneration. We also tested the possibility that photoreceptor loss can be slowed or blocked by interfering with the ceramide signaling pathway of apoptosis in vivo. Retinal ceramide levels increased in rd10 mice during the period of maximum photoreceptor death. Single intraocular injections of myriocin, a powerful inhibitor of serine palmitoyl-CoA transferase, the ratelimiting enzyme of ceramide biosynthesis, lowered retinal ceramide levels to normal values and rescued photoreceptors from apoptotic death. Noninvasive treatment was achieved using eye drops consisting of a suspension of solid lipid nanoparticles loaded with myriocin. Short-term noninvasive treatment lowered retinal ceramide in a manner similar to intraocular injections, indicating that nanoparticles functioned as a vector permitting transcorneal drug administration. Prolonged treatment (10-20 d) with solid lipid nanoparticles increased photoreceptor survival, preserved photoreceptor morphology, and extended the ability of the retina to respond to light as assessed by electroretinography. In conclusion, pharmacological targeting of ceramide biosynthesis slowed the progression of RP in a mouse model, and therefore may represent a therapeutic approach to treating this disease in humans. Transcorneal administration of drugs carried in solid lipid nanoparticles, as experimented in this study, may facilitate continuous, noninvasive treatment of patients with RP and other retinal pathologies.
Retinitis pigmentosa (RP) is a genetic disease causing progressive apoptotic death of photoreceptors and, ultimately, incurable blindness. Using the retinal degeneration 10 (rd10) mouse model of RP, we investigated the role of ceramide, a proapoptotic sphingolipid, in retinal degeneration. We also tested the possibility that photoreceptor loss can be slowed or blocked by interfering with the ceramide signaling pathway of apoptosis in vivo. Retinal ceramide levels increased in rd10 mice during the period of maximum photoreceptor death. Single intraocular injections of myriocin, a powerful inhibitor of serine palmitoyl-CoA transferase, the ratelimiting enzyme of ceramide biosynthesis, lowered retinal ceramide levels to normal values and rescued photoreceptors from apoptotic death. Noninvasive treatment was achieved using eye drops consisting of a suspension of solid lipid nanoparticles loaded with myriocin. Short-term noninvasive treatment lowered retinal ceramide in a manner similar to intraocular injections, indicating that nanoparticles functioned as a vector permitting transcorneal drug administration. Prolonged treatment (10-20 d) with solid lipid nanoparticles increased photoreceptor survival, preserved photoreceptor morphology, and extended the ability of the retina to respond to light as assessed by electroretinography. In conclusion, pharmacological targeting of ceramide biosynthesis slowed the progression of RP in a mouse model, and therefore may represent a therapeutic approach to treating this disease in humans. Transcorneal administration of drugs carried in solid lipid nanoparticles, as experimented in this study, may facilitate continuous, noninvasive treatment of patients with RP and other retinal pathologies.
sphingolipid | apoptosis | electroretinography | morphology R etinitis pigmentosa (RP), one of the leading causes of blindness worldwide, comprises numerous retinal dystrophies of genetic origin frequently caused by mutations in genes essential to rod photoreceptor function and metabolism, resulting in rod cell death and subsequent night blindness (1) . Progressively, cone photoreceptors also die, until all useful sight is lost. Although there is presently no cure for RP, substantial progress has been made to elucidate the genetics and cell biology of these disorders. In particular, rod photoreceptor death in RP is largely thought to occur by apoptosis (2) (3) (4) (5) , although nonapoptotic mechanisms have also been proposed (5) .
Among known proapoptotic cellular messengers, the sphingolipid ceramide is a well-characterized death effector in various experimental models and pathological conditions (6) (7) (8) (9) . Endogenous cellular levels of ceramide increase after stimulation with different proapoptotic factors that cause acute and chronic disease (10, 11) . This increase in ceramide can originate from an activation of de novo biosynthesis, a rise in ceramide hydrolysis from sphingomyelin by the action of neutral or acid sphingomyelinases, or a decrease in ceramide metabolism due to glycosylation, phosphorylation, or deacetylation (12) . An important role for ceramide-mediated apoptosis in neurodegenerative and neuroinflammatory diseases has now been established (10) .
Several lines of evidence suggest that ceramide also mediates apoptosis in retinal photoreceptors (13) . First, in Drosophila models of RP, genetic manipulation of sphingolipid metabolism has protective effects on retinal morphology and function; protection was achieved both by expressing neutral ceramidase in Drosophila eye, to reduce cellular levels of ceramide, and by knocking out one copy of a gene encoding a subunit of serine palmitoyl-CoA transferase (SPT), the enzyme that controls the rate-limiting step of ceramide biosynthesis (14) . In humans, a direct genetic link between retinal degeneration and sphingolipidmediated apoptosis has been established with the discovery that a loss-of-function mutation in CERKL, a gene expressing ceramide kinase-like protein, caused autosomal recessive RP (15, 16) , although debate exists on the pathway leading to cell death in individuals with this mutation (17) . In rat retinal neuronal primary cultures, oxidative stress increased ceramide levels and caused apoptosis, whereas these effects were blocked by addition of docosahexaenoic acid to stimulate antiapoptotic responses (18) . Similarly, in the murine 661W photoreceptor cell line, oxidative stress stimulated acid sphingomyelinase and increased ceramide levels, thereby activating the mitochondrial apoptotic pathway and the caspase cascade (19) . Finally, in a rabbit model of retinal apoptosis, ceramide increased after experimental retinal detachment (20) . Altogether, these studies document that the accumulation of ceramide is associated with retinal degeneration and suggest that pharmacological interventions altering sphingolipid metabolism may have therapeutic potential.
Effective RP therapies might be implemented on biological models that accurately represent retinal degeneration in humans. Recently, the retinal degeneration 10 (rd10) mouse, with a missense mutation in the β-subunit of the rod-specific phosphodiesterase gene (21) , has been shown, through morphological and functional retinal analyses, to be a faithful model of typical human RP (22, 23) . In this mutant, photoreceptors begin to die from apoptosis during the third week of life, after the postnatal period of retinal maturation, and photoreceptor death peaks around postnatal day 24 (P24) (22, 23) . As in typical human RP, rods die first, whereas cones are lost subsequently. Morphologically, the loss of photoreceptors is accompanied by a progressive thinning of the outer retina and consequent reduction in the number of photoreceptor rows from 12 to 14 on P10 to only 2-3 rows on P30. Functionally, rod-mediated retinal responses to light are measurable by electroretinography (ERG) from P14 (the day of eye opening) until P28, although the responses are slow and weak compared with those of wild-type mice (23) .
The availability of the rd10 mouse model of RP permitted us to investigate whether pharmacological treatment with myriocin, a selective inhibitor of SPT, could reduce ceramide and thereby exert a protective effect against retinal degeneration. Myriocin, a fungal metabolite discovered for its immunosuppressant properties, is an atypical amino acid with a long hydrophobic tail, structurally similar to sphingosine (24) . To our knowledge, myriocin has never been tested for protective effects on retinal degeneration. Here we show that retinas of rd10 mice pups have unusually high levels of ceramide which can be reduced by topical administration of myriocin, concomitantly obtaining both protection of photoreceptors from apoptotic death and maintenance of ERG functional response. Furthermore, we show that noninvasive drug delivery can be achieved using eye drops containing a suspension of myriocin-loaded solid lipid nanoparticles.
Results
To determine whether, in the rd10 mouse model of RP, there are altered levels of retinal ceramide, retinas were obtained between P12 and P30 from rd10 mice pups and from wild-type animals of the same genetic background. Total retinal ceramide, normalized to the amount of inorganic phosphate (Pi) from total phospholipid, was similar in the two groups until P16, after which ceramide content started to increase in rd10 animals but continued to slowly decrease in wild-type mice (Fig. 1A ). Significant differences between wild-type and rd10 mice were observed at P21 (P = 0.045, t test) and P30 (P = 0.001), that is, during the period of maximum retinal degeneration in rd10 mice. To test whether these pathologically high levels could be reduced pharmacologically, we administered myriocin by intraocular injection on P19 followed by ceramide quantification on P21. In 14 of 16 mice, myriocin injection into the right vitreous body reduced retinal ceramide levels below that of the left eye, injected with vehicle alone (Fig. 1B) . Overall, myriocin induced a 25.4% reduction in mean ceramide content, from 4.09 pmol/nmol Pi (SD = 1.16) to 3.05 pmol/nmol Pi (SD = 0.97) (P = 0.011, paired t test). This treatment was therefore effective in bringing ceramide to levels considered normal for P21. Similar treatment of wild-type mice also reduced ceramide content, by 17.5%, from a mean of 2.00 pmol/nmol Pi (SD = 0.34) to 1.65 pmol/nmol Pi (SD = 0.12) (P = 0.032, paired t test).
A possible protective effect of intraocular myriocin injection on photoreceptor survival was investigated by assessing the relative abundance of apoptotic photoreceptors in retinas from myriocinand DMSO-treated eyes. Isolated retinas were stained with a fluorescent nuclear dye to identify pycnotic (condensed) nuclei and visualized with confocal microscopy. Retinas from myriocintreated right eyes had fewer intensely stained nuclei than vehicletreated left eyes (Fig. 2 A and B) . Quantitative analysis revealed that 2 d after a single myriocin injection, the number of pycnotic photoreceptor nuclei was reduced by 52.6% (P = 0.007, t test) (Fig.  2C ). To determine whether these protective cellular effects were associated with a maintenance of retinal function, we measured electrical responses to light by ERG 2 d after a single injection of drug or vehicle. ERG traces from myriocin-treated eyes overlapped with those from DMSO-treated eyes (Fig. S1 ). Thus, despite a preservation of cellular viability, a single injection of myriocin did not have measurable functional benefits.
Recognizing that continual pharmacological treatment may be necessary to achieve positive effects on retinal function, we topically administered 0.5 nmol myriocin (1 μL of 3.77 mM solution in DMSO) to the cornea of rd10 mice once daily for 4 d. Microscopic analysis for pycnotic nuclei and ceramide quantification revealed no significant difference between myriocin-and DMSO-treated retinas, suggesting that the drug did not cross the cornea. Therefore, we investigated the possibility of using solid lipid nanoparticles (SLNs) as vehicle to carry the drug across ocular tissues; SLNs are pure lipid particles with a diameter of 40-200 nm. First, we assessed the ability of fluorescently labeled SLNs to reach the interior of the mouse eye. SLNs labeled with the hydrophobic dye N-(7-nitro-2-1,3-benzoxadiazol-4-yl)-1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine (NBD-DPPE) were topically applied to the ocular surface of wild-type mice once daily for 3 d. Confocal microscopy of vertical retinal slices revealed the presence of bright aggregates inside the retina (absent from eyes treated with unlabeled SLNs), mostly in the outer nuclear layer (ONL) and also between the photoreceptors and the retinal pigment epithelium (Fig. 3A) . Spectral analysis confirmed that the observed aggregates contained the NBD-DPPE fluorophore (Fig. 3B ). Similar observations were obtained for SLNs labeled with coumarin and Nile red. These results demonstrated the feasibility of using SLNs to deliver small, lipophilic molecules across the cornea to the photoreceptors and to the retinal pigment epithelium.
SLNs were subsequently prepared with myriocin. The concentration of the drug in different preparations, considered suitable for use in rd10 mice, ranged from 0.4 to 1.0 mM (mean, 0.6 mM). Myriocin-SLNs were administered topically to both corneas of rd10 mice, three times per day for 3 d starting on P19; additional rd10 mice were treated with control SLNs. In retinas collected on P21, mean values of ceramide were 2.49 pmol/nmol Pi (SD = 0.25) in myriocin-treated animals but 4.19 pmol/nmol Pi (SD = 0.92) in control animals (P < 0.001, t test). These results document that myriocin can be effectively administered across the cornea when incorporated into SLNs. However, despite the fact that this treatment reduced retinal ceramide by 40.6% (even more than with a single intraocular injection), still no significant effect was observed on retinal functional responses. Therefore, long-term treatment with myriocin-SLNs was investigated. Starting on P14, rd10 and wild-type (control) mice were treated once daily with myriocin-SLNs or control SLNs. From P21 to P35, different animals underwent ERG testing of retinal function followed by retinal microscopic analysis. Myriocin treatment in wildtype animals had no effect on ERG, which showed the typically large amplitudes of a and b waves (Fig. S2) . In both control and myriocin-treated rd10 mice, mean amplitudes of ERG b waves decreased progressively over time in concomitance with retinal degeneration; similar results were observed for absolute values of mean ERG a waves (Fig. 4) . However, absolute values of the mean amplitudes were larger in myriocin-treated than control animals at all time points except P35, when b-wave amplitudes were essentially identical. Significant differences between the two groups were observed for a-wave amplitudes at P30 and P35. These results indicate that continual topical application of myriocin-SLNs can counteract, to a certain extent, the loss of function due to photoreceptor death in rd10 mice.
The maximum effects of myriocin treatment on retinal responses to light of increasing intensity are illustrated in Fig. 5 , which shows ERG traces from two rd10 mice pups treated for 10 d (P14-P24) with either myriocin-SLNs or control SLNs. In the myriocin-treated animal, there is higher preservation of both a and b waves of the ERG.
To assess the morphological effects of treatment with myriocinSLNs on photoreceptors, we counted the number of photoreceptor rows in the outer nuclear layer, considered a more sensitive measure of photoreceptor survival over long periods of treatment than the number of pycnotic nuclei. Microscopic analysis of vertical retinal sections revealed a protective effect of myriocin on the number of photoreceptor rows, seen as a thicker cross-section of the outer nuclear layer (Fig. 6A ). This effect was significant at both P24 and P30 (Fig. 6B) . The morphology of surviving photoreceptors was preserved as well, as documented by the presence of rhodopsin and cone opsin immunoreactivity in well-organized outer segments of rods and cones, by retention of synaptic terminals of these cells, and by the presence of well-organized dendrites in rod bipolar cells (Fig. S3) .
Finally, in a preliminary assessment of safety of long-term treatment, eyes from anesthetized rd10 and wild-type mice treated for 14 d with myriocin-SLNs were examined under a dissection microscope before enucleation for signs of conjunctiva irritation/edema, which were absent. Cataract and corneal opacities could be excluded by the fact that we successfully recorded ERGs. Nuclear staining of retinal sections with ethidium revealed normal retinal histology. Immunohistochemical analyses did not reveal macrophage infiltration (which would have indicated inflammation) nor microglial activation (Fig. S4 ).
An extension of beneficial effects of myriocin-SLN treatment to retinal cones is anticipated by the morphological preservation of these cells in myriocin-SLN-treated retinas, as well as the recording of a larger cone-driven ERG in rd10 mice treated with myriocin-SLNs for 26 d, compared with control animals (Figs. S3B and S5).
Discussion
This study found that, in the rd10 mouse model of RP, the level of retinal ceramide begins to increase from the third week of life, during the period of maximum photoreceptor loss, whereas in wild-type mice ceramide levels progressively decrease. Single intraocular injections of myriocin, a selective inhibitor of SPT, the rate-limiting enzyme of ceramide biosynthesis, decreased retinal ceramide and reduced the number of apoptotic photoreceptors in the short term. A functional benefit of myriocin was observed after prolonged daily treatment, achieved by the noninvasive, transcorneal administration of the drug contained in solid lipid nanoparticles. In rd10 mice treated with myriocinSLNs for 10-20 d, the pathological decrease in photoreceptor number was slowed, photoreceptor morphology was preserved, and the degeneration of retinas was delayed.
The finding that ceramide levels increase in the rd10 mouse in temporal association with the process of photoreceptor demise (22, 23) provides biochemical evidence that this sphingolipid is involved in the neurodegenerative pathology of RP. This result is therefore in accordance with the knowledge derived from genetic studies that human autosomal recessive RP can be caused by lossof-function mutations in CERKL, an enzyme that lowers ceramide content by phosphorylation (15) . The results are also in agreement with the increased ceramide levels found in tissues from individuals with other pathologies leading to apoptosis, such as brain tissue from Alzheimer's disease patients (25) , and thus provide additional evidence that elevated ceramide is a pathogenetic factor of various diseases. Moreover, the fact that in vivo reduction of retinal ceramide levels slowed disease progression extends to mammals earlier results obtained in Drosophila models of RP (14) . Therefore, these experiments provide a proof of principle that ceramide regulation represents a relevant therapeutic target in RP as in other pathologies (6, 12, (26) (27) (28) (29) (30) . Compared with a previous study in Drosophila models of RP (14) , in which retinal ceramide levels were lowered by genetic manipulation, in this study ceramide levels were lowered pharmacologically. Because noninvasive pharmacological intervention is more easily achieved in humans than gene therapy, the strategy proposed here might become applicable to humans in the long run.
A functional benefit of myriocin was observed only after prolonged treatment but not after a single intraocular administration, despite the fact that both administration methods reduced ceramide levels. The lack of measurable functional effects of single myriocin administrations might be ascribed to the small proportion of photoreceptors rescued from apoptotic death in the short period of study (2 d) . Possibly the corresponding effect on the ERG fell below the sensitivity of this functional test.
This study has a few limitations, the most evident being that chronic administration of myriocin rescued a fraction of photoreceptors for a limited time, mostly delaying the inevitable death process in these cells. However, it has to be considered that prolonging the natural evolution of a disease like RP, which characteristically exhibits a slow progression, can nonetheless be beneficial for patients. Another limitation is that we studied a single genetic paradigm of RP, whereas it is known that this disease is genetically heterogeneous. Different mutations leading to photoreceptor demise could activate different pathways of apoptosis (31), within which the sphingolipidic cascade could play more or less relevant roles, which need to be studied. Overall, the results described here are particularly encouraging, considering that the partial loss-of-function rd10 mutation mimics typical RP forms with moderately aggressive phenotype and good retention of retinal architecture (23) . These are features that portray human RP patients as likely candidates for gene therapy, in which the defective gene is replaced by a functioning one by means of genetically engineered viral vectors (32) . A protective pharmacological approach, based on the noninvasive administration of SPT inhibitors, could prolong the lifespan of photoreceptors in recessive forms of RP, pending gene therapy at a later stage. SPT inhibitors similar to myriocin could therefore contribute to enlarge the panel of bioactive substances already used as neuroprotectants to delay photoreceptor death in this disease (33, 34) . In addition, considering that an increment in the rate of rod survival is known to promote a proportionally longer viability of cones, essential for daylight vision, it is possible that the beneficial effects of delaying the sphingolipid-mediated rod demise would propagate to cones as well. Finally, the particular pharmacological strategy used here, based on the employment of lipophilic, tissue-permeant drops, represents a suitable method to deliver molecules to the inner eye noninvasively. Various carriers (i.e., bio-and nonbiodegradable implants, microspheres, nanoparticles, liposomes, and gels) have been tested experimentally to deliver drugs to the inner eye (35) . The particular advantages of the SLNs used here are their lack of undesirable effects and their suitability for carrying nonpolar, lipophilic compounds. These features can be exploited for drug delivery in retinal disorders other than RP.
In conclusion, this study demonstrates that pharmacological targeting of ceramide biosynthesis has the potential to slow the progression of RP in a mammalian model and therefore may represent a therapeutic approach to treating this disease in humans. Transcorneal administration of drugs carried in solid lipid nanoparticles, as experimented in this study, may also be developed for human patients with other ocular disorders requiring therapy with lipophilic molecules. Quantification of Retinal Ceramide. Mice were anesthetized with an i.p. injection of avertin (0.5 g/mL 2,2,2-tribromoethanol in ter-amylic alcohol; 20 μL/ g body weight). Eyes were quickly removed and retinas were detached, placed in oxygenated artificial cerebral-spinal fluid medium, and frozen on dry ice. Retinal lipid was extracted using the Bligh-Dyer method, and total phospholipid was quantified using the Ames method of Pi determination. Ceramide was determined by diglyceride kinase assay (SI Methods).
Intraocular Injections. Mice were anesthetized as above. Using a dissecting microscope, 500 nL of a 1.88 mM solution of myriocin in DMSO was injected into the right vitreous body using a 10-μL glass Hamilton syringe driven by an oil microinjector. Considering that the injected volume is diluted seven-to eightfold within the vitreous body (37) , this dosage provides an intraocular concentration of ≈0.23 mM myriocin, one order of magnitude higher than that used to inhibit SPT enzymatic activity in single-layer cell-culture studies (38) . An identical volume of DMSO vehicle was injected into the left eyes of the same animals.
Fluorescence Microscopy of Retinas for Pycnotic Photoreceptors. Mice were anesthetized as described earlier, and eyes were enucleated and fixed with 4% paraformaldehyde in 0.1 M sodium phosphate (pH 7.2). Retinas were detached and stained with 2 μM ethidium homodimer 2 (Invitrogen), a fluorescent DNA-intercalating molecule to which fixed tissue is permeable. Whole-mounted retinas were examined under a Leica TCS-SP confocal microscope for the presence of pycnotic (apoptotic) photoreceptor nuclei, brighter than others in the same layer because of the high density of their condensed DNA. The ONL, containing the nuclei of photoreceptors, was sampled along the whole z axis. Photoreceptor pycnotic nuclei were counted on projection images of the ONL in fields of 150.6 × 150.6 μm 2 (32 fields/retina), spaced at 500-μm intervals along the dorsal-ventral and nasal-temporal retinal meridians. The total number of pycnotic photoreceptors for each retina was calculated by multiplying the average density of pycnotic cells in field images by the corresponding retinal area, measured by low-power light microscopy with an image analyzer (Metamorph 5.0, Universal Imaging Corporation).
Electroretinography. Retinal viability and function were assessed by recording flash electroretinograms as previously described (23); details are given in SI Methods. When using mice treated with SLNs, ERG traces were recorded simultaneously from both eyes, identically treated. The possible diffusion of SLNs from one eye to the other made it necessary to use different mice for control and experimental treatments.
Solid Lipid Nanoparticles. Noninvasive, transcorneal treatment of mouse retina was achieved with the use of SLNs, patented by Nanovector srl (SI Methods) (40) . The concentration of myriocin in SLN preparations was determined by extraction with chloroform:methanol:37% HCl (100:200:1 by volume) followed by TLC on silica gel plates in l-butanol:acetic acid:water (3:1:1 by volume). Known amounts of myriocin were loaded on the same TLC plate to generate a standard curve. Separated lipids were visualized by staining with an aqueous solution of 10% CuSO 4 , 8% H 3 PO 2 on a hot plate (180°C) for 3-6 min. Myriocin spots were quantified by densitometry (Gel Doc 2000 and Quantity One software; Bio-Rad).
Topical Administration of SLNs. To determine whether lipophilic molecules contained in SLNs penetrate the inner eye, wild-type mice were treated three times per day with 1 μL SLNs labeled with coumarin, Nile red, or NBD-DPPE; unlabeled SLNs served as control. After 3 d of treatment, vertical retina sections were examined by fluorescence confocal microscopy for the presence and localization of the fluorophore within the retina. To determine whether the observed fluorescence corresponded to the fluorophore administered topically, the emission spectrum from retinal sections was compared with that of a smear of the SLNs on a microscope slide by fluorescent spectral analysis using the confocal microscope's 488-nm laser source. For pharmacological treatment, rd10 mice (66 animals from 10 litters) and wildtype mice (n = 12) were administered once daily with either myriocin-SLNs or control SLNs in both eyes. Each treatment consisted of a double dosage, within a 15-min interval, of 750-1,000 nL/eye (larger volumes were used in older animals). Treatment started on P14 (eye opening) and continued until analysis between P21 and P35.
Fluorescence Microscopy on Retinal Vertical Sections. Retinas from rd10 and wild-type mice that had been treated with SLNs were harvested for morphological analysis. Photoreceptor survival was assessed by counting nuclei in the ONL. Photoreceptor morphology was assessed by immunohistochemistry (SI Methods).
Statistical Analysis. Data were compared by two-tailed unpaired or paired t tests or with the Wilcoxon-Mann-Whitney test when the distribution of data was not normal, as assessed by analysis with SigmaStat v. 3.1 (Systat). Statistical analysis was performed with Origin v. 7.0 (OriginLab) and SigmaStat v. 3.1 software packages for Windows XP. A P value <0.05 was considered significant. Electroretinography. Mice were dark-adapted overnight and anesthetized with an i.p. injection of ketamine (2.5 μg/g body weight) and xylazine (0.3 μL/g body weight). Body temperature was maintained at 37°C. Pupils were dilated by administration of tropicamide (1%) eye drops, and the cornea was kept moist with a methylcellulose solution. For electroretinography (ERG), an electronic flash unit generated a light stimulus of 492 nm whose energy decayed with a τ of 1.7 ms. Full-field stimulation was achieved using a Ganzfeld sphere, and flash intensities were attenuated by neutral-density filters. Mice were subjected to six different flash intensities, each repeated five times, with an interstimulus interval that ranged from 60 s for dim light to 5 min for the brightest flashes. The flash luminance was measured at the corneal plane in photometric units (cd·s/m 2 ) using a Minolta CS100 photometer with a scotopic filter. ERG signals were recorded using coiled gold corneal electrodes. Responses were differentially amplified, band-pass-filtered at 0.3-500 Hz, digitized at 0.25-to 0.5-ms intervals, and stored on disk for processing. Five ERG traces at each flash luminance were averaged before measurements of a-and b-wave amplitudes. The amplitude of the a wave was taken as the difference between baseline and the lowest value, whereas the amplitude of the b wave was measured from the trough of the a wave to the peak of the b wave. The responses to the brightest flashes include mixed rod and cone components. Isolated cone components were obtained by superimposing test flashes on a background of saturating intensity for rods (30 cd·s/m 2 ).
Solid Lipid Nanoparticles. Noninvasive treatment of retinas was achieved with the use of solid lipid nanoparticles (SLNs), pure lipid particles with a diameter of 40-200 nm containing a fatty acid core wrapped in a layer of phospholipids (2) . For feasibility testing, SLNs were loaded with the fluorescent dyes coumarin (Acros Organics), Nile red (Sigma-Aldrich), or N-(7-nitro-2-1,3-benzoxadiazol-4-yl)-1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine (NBD-DPPE; NOF Corporation) at a concentration of 0.01-0.02% (wt/wt). For experimental testing, SLNs were loaded with 0.15% (wt/wt) myriocin (Sigma-Aldrich). Briefly, an oil phase composed of melted stearic acid and Epikuron 200 (96% phosphatidylcholine; Cargill) and a water phase consisting of taurocholic acid sodium salt (Prodotti Chimici Alimentari) and water were combined in a warm microemulsion; fluorescent dyes or myriocin were then added (2) . Butylated hydroxyanisole and D,L-α-tocopherol were included to prevent oxidation. The microemulsion was dispersed in cold water, resulting in the solidification of nanodrops which were then washed by tangential filtration (Amicon 8010 stirred ultrafiltration cell; Millipore). SLN preparations were sterilized by filtration through a 0.2-μm filter before use.
Fluorescence Microscopy on Retinal Vertical Sections. After ERG studies of mice treated with myriocin-SLNs or control SLNs, eyes were removed, fixed for 1 h in 4% paraformaldehyde in 0.1 M sodium phosphate buffer (pH 7.4), infiltrated with 30% sucrose in the same buffer, and frozen at −20°C on a cryostat stage (Leica). Vertical sections of 14 μm were cut, collected on glass microscope slides, and stained with ethidium homodimer 2 before examination by confocal microscopy. Because these mice had been treated for 7-21 d, the effects of myriocin on photoreceptor apoptosis could not be accurately determined by staining for pycnotic nuclei, as the acute phase of photoreceptor degeneration had already passed (3). Therefore, we estimated the number of surviving photoreceptors by counting the rows of nuclei in the outer nuclear layer on high-resolution images of vertical sections obtained from both central and peripheral retinal areas (10 images/retina, each covering a linear retinal extension of 250 μm). Mean values per retina were averaged per group and expressed as mean and SE. Photoreceptor morphology and retinal histology were studied by immunocytochemistry and confocal microscopy on retinal sections as explained in ref. 3 . Primary antibodies used were antirhodopsin (mouse monoclonal; Sigma), anti-cone-specific opsins (rabbit polyclonal; Chemicon), anti-PSD-95 (mouse monoclonal; Chemicon), and anti-protein kinase C (PKC) α (rabbit polyclonal; Sigma). All of the primary antibodies were used at 1:1,000 dilution and revealed with Oregon green-conjugated secondary antibodies. Retinal sections were counterstained with ethidium homodimer to reveal nuclei. Macrophage infiltration (a sign of local inflammation) was assessed on retinal sections from wild-type and rd10 mice treated with topical nanospheres using anti-F4/80 antibodies (rabbit polyclonal; Santa Cruz Biotechnology; used at a dilution of 1:50). Positive controls used for these antibodies were retinal whole mounts from rd10 mouse eyes which had received a massive intraocular injection and thus mechanically damaged and mouse hippocampus, previously treated with kainic acid and thus infiltrated with macrophages. Sections from retinal samples treated with topical nanospheres were also stained with fluorescent Griffonia simplicifolia lectin (Sigma; 1:500) to visualize blood vessels and microglia, with the rationale of detecting possible activation of retinal microglial cells following nanosphere administration. The arrow points to a cluster of spherules in the outer plexiform layer; note the aberrant morphology of these terminals in the control preparation (D′). GCL, ganglion cell layer; INL, inner nuclear layer; IPL, inner plexiform layer; ONL, outer nuclear layer; OPL, outer plexiform layer. 
